“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
As a member of Medicines for Europe Lupin Atlantis Holdings SA (“Lupin”) is committed to adhering to and supporting the Medicines for Europe Code of Conduct (the “Code”). As a transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations and biotechnology products globally Lupin engages independent experts or specialist organizations. Lupin views co-operations between the Pharma industry, Healthcare Professionals (“HCP”) and Healthcare Organizations (“HCO”) as instrumental in the research and development of innovative drugs that allow patients to live healthier, better and longer lives. Lupin deems it as only fair and appropriate to compensate such groups for their time and expertise.
Lupin has not made any other transfer of values to HCPs for fees for service and consultancy or to healthcare or patient organizations in 2019.
What is the legal basis for the disclosure?
The Code requires member companies to disclose Transfers of Value (“ToV”) that could potentially pose a conflict of interest, or to encourage the recipients of the transfers of value to disclose them, where such disclosure would be in the best interest of patients or the public. The Code which applies to all European operations of inter alia all Medicines for Europe member companies aims at establishing a framework of standards and principles that promotes trust, responsible behavior, and respect, between pharmaceutical companies and the healthcare community, including HCPs, HCOs, patients and patient organizations.
What is the definition of Healthcare Community, Healthcare Professional and Healthcare Organization in the context of Lupin’s Code disclosure report?
The term Healthcare Community includes Healthcare Professionals, Healthcare Organizations, Patients and Patient Organizations.
The term Healthcare Professional is defined as any natural person that is a doctor, a member of medical, dental, pharmacy or nursing professions or any other person who, in the course of his or her professional activities, may prescribe, purchase, supply, recommend or administer a medicinal product. For the avoidance of doubt, the definition of Healthcare Professional includes: (i) any official or employee of a government agency or other organization (whether in the public or private sector) that may prescribe, dispense, purchase or administer medicinal products and (ii) any employee of a pharmaceutical company whose primary occupation is that of a practicing Healthcare Professional, but excludes (x) all other employees of a pharmaceutical company and (y) a wholesaler or distributor of medicinal products.
The term Healthcare Organization is defined as any entity (i) that is a healthcare, medical or scientific association or organization (irrespective of the legal or organizational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society or (ii) through which one or more Healthcare Professionals provide healthcare services. For the avoidance of doubt, wholesalers, distributors, and similar commercial intermediaries are not considered Healthcare Organizations.
Patient Organizations are not-for-profit organizations which are patient-focused, and in which patients represent a majority of members in their governing bodies.
What items payments will be disclosed?
A ToV can include anything of value that is provided (or “transferred”) by a Medicines for Europe member company (directly or indirectly via a third party acting at its direction) to a recipient, including monetary payments or in-kind benefits, such as meals, travel, hospitality, etc.
All values disclosed are based on value transfers actually made within the respective category. Such value transfers have been made to HCPs as booked in 2019. All values are disclosed for HCPs which have been engaged by Lupin.
Where is Lupin’s disclosure report published?
Lupin’s disclosure report has been published on the website https://www.lupin.com/our-world/medicines-for-europe-coc-disclosure/
Have HCPs/HCOs consented to Lupin disclosing ToV?
The consent of each HCP or HCO is required before individualized data can be released.
Lupin has sought to secure consent of all the HCOs and HCPs with whom we work but consent is voluntary and can be withdrawn at any time. Lupin believes it is important to make sure our relationships with HCPs are transparent and as such will continue working to encourage our partners to provide consent for full disclosure.
As Lupin has not been able to secure consent from all HCPs for 2019, the respective ToV data is disclosed in aggregate for cases where consent is not available.
How does Lupin define the date of a ToV?
Lupin has included ToVs related to those activities that started as of, or after the 1st January 2019.
For further information about the Code please go to:
For inquiries and information about Lupin’s disclosure of transfers of value to HCPs and HCOs please contact Lupin at email@example.com
Vinita Gupta is the CEO of Lupin Limited (Lupin) and Chairperson of Lupin Inc., (LI) and its US subsidiary, Lupin Pharmaceutical Inc. (LPI).
Vinita is a graduate in pharmacy from the University of Mumbai and earned an MBA degree at the Kellogg School of Management at Northwestern University. Vinita has been instrumental in formulating and executing a strategy that has helped the company emerge as a global pharmaceutical powerhouse; amongst the most exciting growth stories in the pharmaceutical industry. Through a combination of organic growth and strategic acquisitions, she has led the company’s global expansion plans. In particular, she founded, led and established Lupin’s largest region, the United States.
Vinita has been regularly named by Forbes Asia in its Top 50 Power Business women listings for Asia Pacific. Vinita was also recognized by Business Today Hall of Fame – Most Powerful Women in Business in 2016 and was recently named Outstanding Business Woman Leader of the Year by CNBC India Business Leader Awards. She was the winner of the inaugural EY, U.S. 2012 Family Business Award of Excellence and EY Entrepreneur Of the Year® 2012 award winner for Health Services and Technology in Maryland. She is regarded as amongst the most influential Indian Business Women globally.
Vinita along with her brother Nilesh (Managing Director, Lupin Limited) were named Ernst & Young (EY) Entrepreneur of The Year 2015 and won the Forbes India Leadership Awards 2016, Entrepreneur of the Year.
In 2017 Vinita was appointed to the board of directors for Intrexon Corporation. She is also a member of the Global Advisory Board at the Kellogg School of Management at Northwestern University.
Mr. Nilesh Gupta is the MD of Lupin Limited and a member of the Board of Directors. Having joined Lupin in 1996, Mr. Gupta led Lupin’s research, supply chain, manufacturing, quality and regulatory operations, and took charge as the company’s Managing Director in 2013. He has not only been responsible for transforming Lupin’s research program and expanding the company’s manufacturing operations but has also been instrumental in formulating and executing the core strategy that has helped Lupin emerge as a global specialty pharmaceutical major.
Mr. Gupta, along with his sister Vinita Gupta, won the Entrepreneur of the Year award at Forbes India Leadership Awards in 2016 as well as Ernst & Young ‘Entrepreneur of the Year Award’ in India in 2015, also with his sister Vinita Gupta.
Mr. Gupta is a Chemical Engineer from the University Department of Chemical Technology (UDCT) (now ICT), Mumbai, and a graduate with honours from the Wharton School, University of Pennsylvania, USA, where he specialized in healthcare, strategic management and finance.